COMPARACIONES Y RESULTADOS CLINICOS EN EL CANCER DE MAMA: TAMOXIFENO E INHIBIDORES DE LA AROMATASA ADYUVANTES
Columnista Experto de SIIC J. Michael Dixon
en colaboración con
E. Jane Macaskill, MBChB, MRCS. Edinburgh Breast Unit, Western General Hospital Juliette Jackson, MBChB, MRCS. Edinburgh Breast Unit, Western General Hospital Lorna Renshaw, RGN. Edinburgh Breast Unit, Western General Hospital William R. Miller, BSc, PhD, DSc. Edinburgh Breast Unit, Western General Hospital
Fecha de aprobación: 17 de Enero, 2005
Primera edición en siicsalud:
24 de Noviembre, 2005
Sección Artículos originales,
subsección
Expertos del Mundo,
página
http://www.siicsalud.com/des/des046/05n21019.htm
Especialidad principal:
 Oncología.
Especialidades relacionadas:
 Farmacología, Medicina Farmacéutica, Medicina Familiar, Medicina Interna, Medicina Interna, Obstetricia y Ginecología.
|
Dixon JM. Exemestane and aromatase inhibitors in the management of advanced breast cancer
Expert Opinion on Pharmacotherapy
Barber MD, Jack W, Dixon JM. Diagnostic delay in breast cancer
British Journal of Surgery
Gaston MS, Dixon JM. A survey of surgical management of the axilla in UK breast cancer patients
European Journal of Cancer
Somner JEA, Dixon JM, Thomas St J. Node retrieval in axillary lymph node dissections: recommendations for minimum numbers to be confident about node-negative status
Journal of Clinical Pathology
Dixon JM, Young OE. Neoadjuvant exemestane in the treatment of invasive breast carcinoma in postmenopausal women
Case Studies in Breast Cancer
Hayward RL, Dixon JM. Current limits of knowledge in adjuvant and neoadjuvant endocrine therapy of breast cancer: the need for more clinical research
Surgical Oncology
Dr. J. Michael Dixon
Dirección profesional:
Edinburgh Breast Unit, Western General Hospital, Edinburgh, Crewe Road South, Edinburgh, Scotland, EH4 2XU Reino Unido
|
